Semaglutide Shows Weight Loss Gains in Liver Disease
Novo Nordisk reports real-world data on semaglutide 2.4 mg in adults with MASH, presented at a Denver liver conference.
Updated on Nov. 7, 2026 in Weight Loss
Novo Nordisk announced real-world data from two retrospective studies of semaglutide 2.4 mg in adults with metabolic dysfunction-associated steatohepatitis (MASH). The results were presented at the AASLD, The Liver Meeting 2026 in Denver, Colorado.
Why it matters
MASH affects a large population worldwide, and the studies suggest semaglutide was associated with greater weight loss and liver-related measures than resmetirom or no semaglutide over the study periods. The findings come from observational data and do not establish causation, so they are unlikely to settle questions about how the drug compares with other treatments.
The PLATINUM-Truveta study included 2,873 adults who started semaglutide 2.4 mg and 2,285 who started resmetirom, while RHODIUM-2 compared 2,479 semaglutide initiators with 70,702 non-initiators. Both studies were observational, and the treatment groups were not randomly assigned.
The players
Novo Nordisk
A Danish pharmaceutical company best known for developing semaglutide, the active ingredient in several widely prescribed diabetes and weight-management medications.
AASLD
The American Association for the Study of Liver Diseases, a professional society whose annual Liver Meeting is a major forum for hepatology research.
The details
The studies used de-identified electronic medical record data from Truveta across US health systems from June 2021 through March 2026, applying statistical methods to reduce confounding. Semaglutide 2.4 mg is FDA-approved under accelerated approval for adults with MASH and moderate-to-advanced liver scarring, but not for cirrhosis.
Timeline
June 2021 through March 2026: period of Truveta electronic medical record data used in both studies.
November 6, 2026: Novo Nordisk announced the new real-world data.
Health Landscape
Semaglutide's accelerated approval for MASH in adults with moderate-to-advanced liver scarring marks an early regulatory step for a disease affecting more than 250 million people globally. These retrospective findings add real-world context to a therapeutic area where projected advanced MASH cases are expected to rise by over 160% between 2015 and 2030.
For adults with MASH, these findings suggest that treatment discussions may weigh weight-loss and liver-related effects alongside other options, though individual results will vary. Patients should consult their clinicians before making any changes to their treatment plans.
The takeaway
Real-world data can complement clinical trials by showing how a drug performs in everyday care, but observational results should be read as hypothesis-generating rather than definitive. Readers with MASH should discuss the trade-offs of any treatment with their physician.
Further reading
For more on how these medications are being studied across conditions, see Weight Loss coverage.
Source note: This article includes information reported by Økonomisk Ugebrev.
